| abstract |
Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, R5, and R6 are as defined herein. Pharmaceutical compositions containing a compound of this invention, as well as methods relating to the use thereof, are also disclosed. |